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ABSTRACT
Objectives: Current musculoskeletal outcome tools
are fragmented across different healthcare settings and
conditions. Our objectives were to develop and validate
a single musculoskeletal outcome measure for use
throughout the pathway and patients with different
musculoskeletal conditions: the Arthritis Research UK
Musculoskeletal Health Questionnaire (MSK-HQ).
Setting: A consensus workshop with stakeholders
from across the musculoskeletal community,
workshops and individual interviews with a broad mix
of musculoskeletal patients identified and prioritised
outcomes for MSK-HQ inclusion. Initial psychometric
validation was conducted in four cohorts from
community physiotherapy, and secondary care
orthopaedic hip, knee and shoulder clinics.
Participants: Stakeholders (n=29) included primary
care, physiotherapy, orthopaedic and rheumatology
patients (n=8); general practitioners, physiotherapists,
orthopaedists, rheumatologists and pain specialists
(n=7), patient and professional national body
representatives (n=10), and researchers (n=4). The four
validation cohorts included 570 participants (n=210
physiotherapy, n=150 hip, n=150 knee, n=60 shoulder
patients).
Outcome measures: Outcomes included the
MSK-HQ’s acceptability, feasibility, comprehension,
readability and responder burden. The validation cohort
outcomes were the MSK-HQ’s completion rate, test–
retest reliability and convergent validity with reference
standards (EQ-5D-5L, Oxford Hip, Knee, Shoulder
Scores, and the Keele MSK-PROM).
Results: Musculoskeletal domains prioritised were
pain severity, physical function, work interference,
social interference, sleep, fatigue, emotional health,
physical activity, independence, understanding,
confidence to self-manage and overall impact. Patients
reported MSK-HQ items to be ‘highly relevant’ and ‘easy
to understand’. Completion rates were high (94.2%),
with scores normally distributed, and no floor/ceiling
effects. Test–retest reliability was excellent, and
convergent validity was strong (correlations 0.81–0.88).
Conclusions: A new musculoskeletal outcome measure
has been developed through a coproduction process
with patients to capture prioritised outcomes for use
throughout the pathway and with different
musculoskeletal conditions. Four validation cohorts
found that the MSK-HQ had high completion rates,
excellent test–retest reliability and strong convergent
validity with reference standards. Further validation
studies are ongoing, including a cohort with rheumatoid/
inflammatory arthritis.
INTRODUCTION
Taken together, osteoarthritis, inﬂammatory
disorders and common musculoskeletal con-
ditions such as back, neck, shoulder, hip and
knee pains now represent the single greatest
cause of years lived with disability.1 Finding
ways to prevent this impact on quality of life
from increasing is a signiﬁcant and
Strengths and limitations of this study
▪ A new musculoskeletal health questionnaire
(MSK-HQ) has been successfully developed
through a coproduction process with patients.
▪ The MSK-HQ captures key outcomes that were
shown to be highly relevant to patients across a
range of musculoskeletal conditions and settings.
▪ Promising measurement properties were found
in four different musculoskeletal cohorts, with
high completion rates, excellent test–retest reli-
ability, and strong convergent validity with refer-
ence standards.
▪ Limitations of the study were the lack of a rheuma-
toid/inflammatory arthritis validation cohort and
that the MSK-HQ’s responsiveness has yet to be
tested.
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important challenge.2 In the UK, these conditions are
primarily managed in primary care, with referral to
interface clinics and secondary care for more complex
management or specialist treatment and surgery such as
rheumatology or joint replacement. Until recently, many
musculoskeletal services have been provided within dis-
tinct, discrete silos of care that have failed to address the
long-term nature of these conditions or the fact that
many patients have multiple musculoskeletal symptoms
in more than one region of the body.3–5 Evidence exists
for a wide variation in service performance, with a lack
of consistency and continuity of care across the clinical
pathway and poor adherence to the National Institute of
Health and Care Excellence’s (NICE) Quality Standards
of Care for musculoskeletal conditions.6 7 Current
outcome tools and data collection systems are disparate
and fragmented across different healthcare settings, and
as a consequence, although many healthcare commis-
sioners are aiming to reorientate services from their
traditional focus on acute and episodic care towards
better prevention, self-care and integrated primary
care,8 there is a lack of clinical tools that link together
different parts of the clinical pathway.
Patient-reported outcome measures (PROMs), which
are short, self-completed questionnaires designed to
capture patient views about their health status,9 are
ideally suited to areas such as musculoskeletal health
where disease impact is not easily captured using bio-
markers. PROMs are therefore increasingly valued for
their use in evaluating the performance of musculoskel-
etal services alongside measures of patient safety, patient
experiences and service indicators. One example of the
ability of PROM data to act as a catalyst for raising stan-
dards has been evidenced through the UK’s National
PROMs Programme which provides online reports10
identifying the worst and best healthcare providers for
four high-cost surgical procedures (hip and knee
replacement, varicose vein removal and hernia repair).
Building on early successes from this initiative, there
have been growing calls for new and practical musculo-
skeletal PROMs that can measure musculoskeletal health
status across the pathway and across different pain pro-
blems. The vision is for the routine and systematic use of
a single musculoskeletal PROM throughout different
parts of the service to drive forward quality improvement
and ensure that exemplar services are identiﬁed and
emulated.
The overall aim of this project was to develop and
validate a new musculoskeletal PROM: the Arthritis
Research UK Musculoskeletal Health Questionnaire
(MSK-HQ). Prerequisites for this MSK-HQ were as
follows: it should be coproduced with patients and clini-
cians to identify aspects of health that were meaningful
to both; it should aim to provide a holistic view of the
impact on a person’s musculoskeletal health throughout
the clinical pathway, and be applicable for use by differ-
ent MSK health professionals; it should be generic
across different MSK conditions and help identify
individual treatment targets; it should be sensitive to
change to enable longitudinal measurement and the
monitoring of changes over time; it should demonstrate
robust psychometric properties; and ﬁnally, it should be
easily interpretable and feasible for use in routine, busy
clinical practice.
In this study, we address the following three objectives:
(1) identifying and prioritising key outcomes to include
in the MSK-HQ; (2) developing the draft MSK-HQ
through a process of face and content validity testing;
and (3) the initial validation study to report the
MSK-HQ’s scoring, completion rate, test–retest reliability,
convergent validity and internal consistency in primary
and secondary care musculoskeletal cohorts.
METHODS
Objective 1: identifying and prioritising key outcomes to
include in the MSK-HQ
Scoping exercise
A brief scoping exercise was conducted by an experi-
enced systematic reviewer to identify health outcome
domains highlighted within primary and secondary
research used to describe disease impact and character-
ise improvement for patients with arthritis, inﬂammatory
conditions and musculoskeletal pain. Intervention
studies were searched on the MEDLINE database from 1
January 2000 to 1 December 2013, and data were
extracted using the following headings: author, date,
clinical setting, domains used to characterise patients
and the primary outcome. The purpose of this exercise
was to identify a list of potentially relevant outcomes to
inform the following consensus process.
Consensus workshop
A consensus workshop with stakeholders from the UK
musculoskeletal community was held to identify and
prioritise key musculoskeletal outcome domains for in-
clusion in the MSK-HQ. Stakeholders (n=29) in attend-
ance included patients (n=8; from primary care,
orthopaedic and rheumatology services), clinicians (n=7;
including general practitioners (GPs), physiotherapists,
orthopaedists, rheumatologists and pain specialists),
national musculoskeletal patient and professional body
representatives (n=10) and musculoskeletal researchers
(n=4). All participants provided informed written
consent, and patient representatives were remunerated
in line with INVOLVE guidance.11 The workshop used a
nominal group technique12 with patients having an
equal voice. Initially, a study presentation was given
including information on the outcome domains identi-
ﬁed from the literature review. Then small group discus-
sions (including a dedicated patient group) were held to
identify potential domains for inclusion, followed by a
full group discussion, and blind vote to retain domains
with broad consensus (deﬁned as >50% of participants).
Finally, individual participants ranked a ﬁnal list of
domains. Participants were also asked to discuss the
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maximum number of items within the MSK-HQ and the
type of response options it would include.
Objective 2: developing the draft MSK-HQ through a process
of face and content validity testing
Face and content validity testing
Having obtained a ﬁnal list of prioritised musculoskeletal
outcome domains, single items for each domain were for-
mulated using relevant existing outcome domain ques-
tionnaires, expertise within the team and an iterative
process with patients to optimise the wording of items
and to ensure that each question appropriately captured
its respective prioritised domain (content validity). The
formal iterative process to improve the MSK-HQ’s face
validity and content validity involved holding four focus
groups, with six individual patients. The ﬁrst two focus
groups were held at Keele University with three patients,
two of whom had osteoarthritis and the third had back
pain. The next two focus groups were held at Oxford
University with three patients, one with rheumatoid arth-
ritis, and two with experience of orthopaedic surgery
(hip and knee). In addition, before and after each work-
shop, the MSK-HQ was iteratively improved through a
cognitive interview with each of the six patients using
a combination of verbal probing and think-aloud
methods13 to establish the tool’s acceptability, feasibility,
comprehension, readability and perceived responder
burden.
Stakeholder acceptability
To determine the MSK-HQ’s acceptability to the wider
musculoskeletal community, a second workshop with the
same stakeholders involved in the ﬁrst consensus work-
shop was held to present the ﬁnal candidate MSK-HQ
prior to psychometric testing. A blind vote was used to
conﬁrm whether the stakeholders agreed that the
measure was acceptable for validation testing (>80%
agreement required) and to agree the context in which
the MSK-HQ should and should not be used. The cul-
mination of this process was a candidate MSK-HQ ready
for psychometric testing.
Objective 3: initial measurement properties of the
MSK-HQ
Design and setting
Community physiotherapy cohort
A cross-sectional validation cohort was derived from
consecutive consulters in community musculoskeletal
physiotherapy clinics in ﬁve UK West Midlands towns
(Middlewich, Congleton, Wombourne, Cheadle and
Wolverhampton). These clinics provide individual,
face-to-face treatments within the English National
Health Service (NHS) for patients referred from their
GP. Participants received usual physiotherapy care
according to clinical need. Consecutive adult (≥18 years)
consulters with a musculoskeletal disorder were invited
to participate having received a study information pack
with their community physiotherapy appointment.
No further inclusion/exclusion criteria were used except
that patients had to be referred to the clinic by their GP,
with the expectation that the cohort would comprise
patients with a heterogeneous range of diagnostic groups
and unspeciﬁed presenting musculoskeletal problems.
Participants completed the MSK-HQ and other measures
before the start of treatment at the ﬁrst clinic visit and
again at the second visit (typically 2 weeks later) to inves-
tigate test–retest reliability of the tool.
Secondary care orthopaedic cohorts
Three validation cohorts were recruited from the
Nufﬁeld Orthopaedic Centre in Oxford by introducing
the MSK-HQ into routine questionnaires used in the
assessment pathway for patients listed for orthopaedic
surgery for the knee, hip and shoulder. Adult partici-
pants (≥18 years) completed a standard set of question-
naires at their preoperative assessment clinic, and a
subset completed the MSK-HQ ∼5 days later at home for
MSK-HQ reliability testing.
Population descriptors: Baseline population descriptors
were measured consistently across cohorts and included
measures of demographic data (age, gender, work
status) and pain characteristics: pain-related days off
work over past 3 months, pain episode duration, number
of pain-related visits to their GP in the past 3 months
and outcome expectations (using a numerical response
scale from 0 ‘it will get worse’ to 10 ‘it will be cured’).
Reference standard measures of construct validity: All
patients completed questionnaires containing the
candidate MSK-HQ and the EQ-5D-5L.14 The EQ-5D-5L
utility score was calculated using the UK Crosswalk value
set.15 In addition, the orthopaedic cohort patients
completed the Oxford Hip Score (OHS), Oxford Knee
Score (OKS), Oxford Knee Score-Activity & Participation
Questionnaire (OKS-APQ) and Oxford Shoulder Score
(OSS) for, respectively, hip, knee and shoulder problems,
and the physiotherapy cohort completed the six-item
Keele MSK-PROM.16
Test–retest reliability
To identify patients with stable symptoms, when patients
completed the second MSK-HQ for test–retest reliability
assessment, they also completed a patient global rating of
improvement question, a recommended core outcome in
chronic musculoskeletal and osteoarthritis trials.17 The
item asked, “Overall compared to the start of treatment,
my symptoms are: much better, better, same, worse, or
much worse.” Stable patients were deﬁned as those who
reported that their symptoms were the ‘same’ at retest.
Scoring the MSK-HQ
To ensure simplicity of the MSK-HQ scoring, which sta-
keholders emphasised was important during the consen-
sus workshops, scores from all 14 items are summed
together (responses coded from ‘not at all’=4 to
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‘extremely’=0, except for items 12 and 13, which have
the response options in the reverse order) providing a
range from 0 to 56, with higher scores indicating better
MSK health status.
Statistical analysis
MSK-HQ acceptability was assessed using response rates
and completeness of data by examining the normal dis-
tribution of MSK-HQ scores and ﬂoor and ceiling effects
(<10% threshold). Complete case analyses were per-
formed throughout the analyses for the MSK scores,
with no imputation for missing values. A person–item
map for a partial credit Rasch model was performed in
order to build a hypothetical unidimensional line along
which items and persons are located according to their
difﬁculty and ability.18
The MSK-HQ items were tested for internal consistency
using Cronbach’s α to establish whether items may be
treated as a single additive scale using baseline and retest
data. The SEM was calculated using SD ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃð1 RÞp .19
To examine test–retest reliability between MSK-HQ
scores at baseline and retest, Kendall’s coefﬁcient of
concordance (W) was calculated to examine individual
item agreement,20 and the intraclass correlation coefﬁ-
cient (ICC—based on a two-way random effect, absolute
agreement model) was used to test overall score agree-
ment in the combined data set and as a sensitivity ana-
lysis for each individual cohort. An ICC above 0.70 is
considered acceptable/good.21
To examine the convergent validity of the MSK-HQ
against reference standard measures, we used Pearson’s
and Spearman’s correlations between sum scores at base-
line.21 The a priori hypothesis was that the MSK-HQ
total score (higher=better) would follow a similar
response pattern to those on reference standard scales.
The sample size for each validation cohort was calcu-
lated from the minimum number of patients recom-
mended to investigate MSK-HQ test–retest reliability
among a conservatively estimated 30% reporting stable
symptoms. Using the Donner and Eliasziw22 approach
for estimating sample size for reliability testing, we calcu-
lated that 102 people were needed for the physiotherapy
cohort and orthopaedic cohorts combined, to detect a
minimum acceptable ICC of 0.70, assuming a true ICC
of 0.80, with a power of 80% and 5% signiﬁcance level.
All analyses were conducted in STATA/IC V.14
(StataCorp LP., 2015), SPSS V.22 (IBM Corp, 2013) and
Statistical software-R V.3.2.2 (The R Foundation for
Statistics, 2015).
RESULTS
Objective 1: identifying and prioritising key outcomes to
include in the MSK-HQ
Scoping review and consensus workshop
The brief scoping review produced a list of over 75 exist-
ing outcome domains (available from the authors on
request) from the literature. This was presented at the
consensus workshop. Following the consensus process,
participants identiﬁed and prioritised the following key
outcomes for inclusion in the MSK-HQ (in priority
order): severity of pain/stiffness (in the day and night),
physical function (walking and dressing), physical activ-
ity level, pain interference (with work/daily routine and
with social activities/hobbies), difﬁculty with sleep,
fatigue/low energy levels, emotional well-being (anxiety
and mood), understanding of diagnosis and treatment,
conﬁdence to self-manage (pain self-efﬁcacy), inde-
pendence and overall impact from symptoms. There
were no marked differences in domain preferences
between patients, clinicians and other stakeholders, and
at the conclusion of the process, there was strong
endorsement across the stakeholder community for the
key domains that emerged. It was agreed that the
MSK-HQ should include no more than 15 items and
would use a response scale based on Likert ‘severity’
response options.
Objective 2: developing the draft MSK-HQ through a process
of face and content validity testing
A summary of the patients’ feedback about the face val-
idity, content validity, recall period, response scale,
format and layout, sensitivity to change and application
of the MSK-HQ is provided in table 1.
On average, the MSK-HQ took around 2 min to com-
plete. The MSK-HQ Flesch reading ease test score is 65.9,
meaning that it is easily understood by 13–15-year-old stu-
dents and is easier to read than many PROMs such as the
EQ-5D-5L which scores 61.3.
The MSK-HQ is available online via General Info:
http://isis-innovation.com/health-outcomes/ and a Licence
request: http://process.isis-innovation.com/
Examples of the MSK-HQ items are shown in ﬁgure 1.
Objective 3: initial measurement properties of the MSK-HQ
Study sample
There were 570 patients in total who consented to par-
ticipate in the 4 studies (210 physiotherapy patients, 150
hip, 150 knee, and 60 shoulder). Baseline population
characteristics for the overall sample and for each cohort
are summarised in table 2, showing a mean age of
56.99 years (SD 16.54) with 65.19% women. The median
pain episode duration was 6.58 months (SD 4.42), and
the mean EQ-5D-5L utility score was 0.49 (SD 0.26).
MSK-HQ acceptability/completion rates
The MSK-HQ was acceptable to patients, with complete
MSK-HQ data available for 537/570 patients (94.2%).
Across the Hip, Physiotherapy, and Shoulder cohorts,
there was around 3% missing data (see table 2), but the
proportion of missing data was substantially higher in
the Knee cohort at 14.7%, as data entry was not checked
in clinic. In data for the four cohorts combined, the best
completed MSK-HQ item was the ‘walking’ (item 3) with
4/570 (0.07%) missing responses, while the ‘fatigue/low
energy’ (item 10) had the most missing responses 9/570
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(1.6%). Within the knee cohort (n=150), missing
responses were higher than for other cohorts but were
spread fairly evenly across all 14 MSK-HQ items varying
from 3/150 people (2%) for the ‘walking’, ‘social activ-
ities’ and ‘sleep’ items to 7/150 people (4.7%) for the
‘understanding of condition’ item. The person–item
map for a partial credit Rasch model revealed that
across the combined cohorts, the most difﬁcult item to
get a lower severity score was ‘overall impact’ (item 14)
and that ‘washing/dressing’ (item 4) was the easiest
item to get a lower severity score (see ﬁgure 2). No
weighting was given to any items in order to ensure that
the MSK-HQ is simple to use and interpret in clinical
practice. The MSK-HQ scores for all the cohorts com-
bined were normally distributed with an overall mean
score of 28.62 (9.61) from a possible range of 0–56. No
ﬂoor or ceiling effects were observed. Within the four
cohorts, the Hip cohort had the worst overall MSK
health status with a mean (SD) MSK-HQ total score of
24.93 (8.27). Overall MSK health status was about 3
points more favourable across each of the other three
cohorts with mean (SD) MSK-HQ scores for Knee,
Physiotherapy and Shoulder cohorts being 27.54 (9.03),
30.54 (9.56) and 33.48 (10.54), respectively. The SEM
for the MSK-HQ was 5.52.
Internal consistency
Analysis of internal consistency demonstrated that the
total score can be adequately considered as one scale,
with a mean Cronbach’s α at a baseline of 0.88. α Values
for each individual item were similar and are provided
in table 3. The item on ‘interference with work/daily
routine’ was the most correlated item to the total
MSK-HQ score (0.76), and responses for two items
(understanding your condition and conﬁdence to self-
manage) were shown to correlate weakly (−0.04 and
0.32, respectively) with the total MSK-HQ score. The
retest data showed similar patterns of results.
Test–retest reliability
There were 370/537 patients (70.0%) with retest
MSK-HQ data available with a mean (SD) time interval of
5.92 (4.63) days. There were 245 (66.2%) patients report-
ing ‘stable’ symptoms between the two time points, with
73 (19.8%) reporting being ‘better’ and 52 (14%)
Table 1 Summary of patient feedback
General qualities Patient feedback
Face validity ▸ Patients felt most questions were relevant, easy to understand and answer.
▸ Patients tended to interpret the questions correctly as they were intended.
▸ Some queried if the MSK-HQ may be difficult for individuals with multiple MSK conditions, eg,
‘which condition do I talk about?’
Content validity ▸ Patients considered that all items were highly relevant and important to their daily lives.
▸ Patients agreed that the MSK-HQ covered most prioritised domains they wanted.
▸ Other domains suggested included:
– Severity of and/or length of time with stiffness during the day and at night,
– Effectiveness of pain relief treatments/therapies,
– Impact on social activities,
– A general change in health question.
Recall period ▸ Patients correctly used a 2-week recall period for most questions.
Response scale ▸ All patients generally agreed that the response scale and descriptive responses were
appropriate.
▸ The use of ‘extremely’ as the final response option was changed as it was not always
appropriate.
Format and layout ▸ Patients considered the layout and format to be appropriate.
▸ Some minor issues included:
– The MSK-HQ instructions and spacing of items,
– Response options descriptors should be close to tick boxes,
– Labelling of the items was improved.
▸ Patients did not generally notice the scoring codes for each item response. A few mentioned
that they are used to see these on questionnaires and did not think that it was a problem
having them included.
Sensitivity to change ▸ Patients suggested that all domains were likely to change over time, depending on stage or
severity of their condition:
– Domains most likely to change: walking, pain, sleep, physical activities and impact,
– Domains least likely to change: dressing and help needed.
Application and
administration
▸ Patients thought that the MSK-HQ would be useful to monitor health regularly.
▸ The generic nature of the questionnaire was mostly perceived to be a positive thing, so it can
be used across different MSK conditions.
▸ Patients suggested that they would be happy to complete it themselves at home. Completion
every 3 months was suggested as a suitable follow-up period.
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‘worse’. Within the group with ‘stable’ symptoms, the
MSK-HQ total score agreement ICC was 0.84 (95% CI
0.77 to 0.89, n=226), demonstrating ‘excellent’ reliability.
The sensitivity analysis for each individual cohort
revealed that the ICC within the Hip cohort was 0.91
(95% CI 0.85 to 0.95, n=60), Knee cohort was 0.79 (95%
CI 0.67 to 0.87, n=63), Physiotherapy cohort was 0.80
(95% CI 0.45 to 0.91, n=79) and Shoulder cohort was
0.93 (95% CI 0.84 to 0.97, n=24). Kendall’s coefﬁcient of
concordance for individual item agreement in the com-
bined data set ranged from 0.72 for the ‘understanding
of condition’ and ‘conﬁdence in managing symptoms’
items to 0.90 for the ‘sleep’ item. Details of inter-rater
agreement for each of the 14 items are given in table 3.
Convergent validity
Pearson’s and Spearman’s rank correlations of the
MSK-HQ with the EQ-5D-5L for the overall combined
data were strong, being 0.80 and 0.81, respectively.
Table 4 demonstrates strong correlations between the
MSK-HQ and reference standards for each of the four
cohorts, including the MSK-PROM, OHS, OKS and OSS,
in particular with the OKS and OSS with Spearman’s of
0.88 and 0.86, respectively.
DISCUSSION
This study describes the successful development and
initial psychometric validation of the MSK-HQ. This new
outcome measure has been coproduced with patients
Figure 1 Example items from the MSK-HQ. MSK-HQ, Musculoskeletal Health Questionnaire.
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and clinicians to measure the holistic impact of an MSK
condition on a person’s health, regardless of the loca-
tion of their MSK pain or where on the clinical pathway
an individual is currently receiving care. The ﬁrst phase
of the project successfully identiﬁed and prioritised key
outcomes that a broad range of MSK patients and clini-
cians ranked as the most important for identifying and
monitoring the impact from an MSK condition on
overall MSK health status. These domains included
severity of pain/stiffness (in the day and at night), phys-
ical function (walking and dressing), physical activity
level, symptom interference (with work/daily routine
and with social activities/hobbies), difﬁculty with sleep,
level of fatigue/low energy levels, emotional well-being
(anxiety and mood), understanding of diagnosis and
treatment, conﬁdence to self-manage (pain self-
efﬁcacy), independence and overall impact from symp-
toms. The wording for single items to capture each of
these domains was successfully optimised through a
process of face and content validity testing with users,
resulting in 14 items that patients with a range of MSK
conditions felt were ‘highly relevant’ to their lives and
‘easy to understand’.
Our validation study included 570 MSK patients from
4 different cohorts with a range of MSK conditions from
primary/community and secondary care settings.
The results demonstrated that the MSK-HQ was well
completed, has excellent test–retest reliability and has
strong convergent validity with reference standards. The
ﬁndings were consistent across the four cohorts
Table 2 Baseline characteristics overall and by each cohort (values represent mean (SD) unless otherwise indicated)
Variable
All participants,
n=570
Physio,
n=210
Hip,
n=150
Knee,
n=150
Shoulder,
n=60
Demographic variables
Age (years) 56.99 (16.54) 53.53 (15.45) 55.62 (17.21) 65.68 (13.80) 51.54 (17.15)
Sex, n (%) female 313 (65.19) 112 (53.59) 88 (60.69) 89 (62.24) 24 (40.00)
Employment status, n (%) yes
working
263 (48.88) 126 (60.29) 64 (45.07) 40 (30.53) 33 (58.93)
Taken time off work for pain, n (%) 56 (21.29) 27 (21.42) 15 (23.43) 8 (20.00) 6 (18.18)
Pain duration (months) 6.58 (4.42) 4.84 (2.95) 8.41 (5.76) 8.16 (4.69) 9.13 (4.13)
No. of pain-related visits to GP,
past 3 months
1.39 (1.45) 1.53 (0.93) 1.47 (2.05) 1.37 (1.45) 0.73 (0.99)
Outcome expectations (NRS) 9.25 (1.63) 8.38 (1.77) 9.82 (1.18) 9.79 (1.27) 9.67 (1.56)
Clinical variables
MSK-HQ total score 28.62 (9.61) 30.54 (9.56) 24.93 (8.27) 27.54 (9.03) 33.48 (10.54)
EQ-5D-5L utility score 0.49 (0.26) 0.55 (0.25) 0.40 (0.24) 0.45 (0.26) 0.56 (0.25)
Keele MSK-PROM 17.44 (4.45)
OHS 20.4 (8.62)
OKS 20.89 (8.84)
OSS 29.62 (10.34)
Missing data for MSK-HQ score: all participants, n=33 (5.8%); Physio cohort, n=5 (2.4%); Hip cohort, n=4 (2.7%); Knee cohort, n=22 (14.7%);
Shoulder cohort, n=2 (3.3%).
EQ-5D-5L, EuroQol 5 level; MSK-HQ, Musculoskeletal Health Questionnaire; NRS, numerical rating scale; OHS, Oxford Hip Score; OKS,
Oxford Knee Score; OSS, Oxford Shoulder Score.
Figure 2 A person–item map for the Rasch partial credit model presents item response difficulty.
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suggesting promising initial cross-sectional psychometric
properties of the MSK-HQ. As might be expected,
patients’ MSK health status (measured by the MSK-HQ
total score) was shown to be worst among secondary
care patients awaiting hip surgery (mean=24.93) and
knee surgery (mean=27.54), and was less severe among
those receiving community physiotherapy (mean=30.54).
While the MSK-HQ is a multidimensional measure, its
high internal consistency across items (Cronbach’s α of
0.88) suggests that it can be considered as one scale for
overall MSK health status with the MSK-HQ total score.
To ensure simplicity of the MSK-HQ scoring in routine
clinical practice, which emerged as important during
the consensus workshops, scores from individual items
are summed together, providing a range from 0 to 56.
The MSK-HQ overall score is not a score of a single con-
struct (reﬂective model), but a sum of items from differ-
ent domains measuring overall musculoskeletal health
status (formative model). Alternative scoring approaches
including weighting items were discussed at the second
stakeholder workshop, and it was agreed that ﬁrst, a
non-weighted approach was better suited to using the
tool in routine practice, and second that the provision
of a single additive scale was clinically useful in helping
to evaluate the overall impact of the musculoskeletal
condition on the individual. The study identiﬁed that
the test–retest reliability of the MSK-HQ’s total scores
among ‘stable’ patients between the baseline and retest
time points (using ICCs) was ‘excellent’ overall. In add-
ition, as a sensitivity analysis, we examined the test–retest
reliability separately for each of the 4 cohorts, which
found that the ICC varied from 0.79 to 0.93. It should
be noted, however, that it is unwise to use these ﬁgures
to directly compare the reliability of the tool in the dif-
ferent cohorts due to the potential for bias as the study
was not powered for this sensitivity analysis and the pro-
portion of ‘stable’ patients differed across the four
cohorts. Finally, the strong correlations with different
Table 3 Internal consistency of the MSK-HQ at baseline and retest
Baseline, n=537 Retest, n=376
Baseline and
retest
Item Mean (SD) ritem-rest α= Mean (SD) ritem-rest α= N Kendall’s W
MSK-HQ Total (0, 56) 0.88 0.92 358 0.91
1. Pain/stiffness during the day 1.52 (0.91) 0.69 0.87 1.71 (0.89) 0.76 0.91 379 0.83
2. Pain/stiffness at night 1.65 (1.09) 0.60 0.87 1.96 (1.12) 0.65 0.92 379 0.87
3. Walking 2.11 (1.16) 0.57 0.88 2.23 (1.18) 0.69 0.91 380 0.89
4. Washing/dressing 2.77 (1.02) 0.60 0.87 2.89 (0.97) 0.64 0.92 382 0.86
5. Physical activity levels 1.52 (1.14) 0.56 0.88 1.72 (1.29) 0.70 0.91 379 0.83
6. Work/daily routine 1.81 (1.03) 0.76 0.87 2.11 (1.04) 0.81 0.91 381 0.83
7. Social activities and hobbies 1.80 (1.11) 0.63 0.87 2.09 (1.17) 0.74 0.91 381 0.82
8. Needing help 2.62 (1.21) 0.65 0.87 2.70 (1.19) 0.73 0.91 380 0.88
9. Sleep 1.73 (1.28) 0.56 0.88 1.97 (1.35) 0.60 0.92 382 0.90
10. Fatigue or low energy 2.22 (1.08) 0.63 0.87 2.27 (1.07) 0.71 0.91 381 0.87
11. Emotional well-being 2.47 (1.16) 0.64 0.87 2.65 (1.12) 0.70 0.91 382 0.84
12. Understanding condition 2.60 (1.10) −0.04 0.90 2.95 (0.80) 0.10 0.93 379 0.72
13. Confidence in managing 2.39 (0.99) 0.32 0.89 2.50 (0.94) 0.41 0.92 382 0.72
14. Overall impact 1.42 (0.88) 0.74 0.87 1.59 (0.96) 0.79 0.91 381 0.82
n is the number of individuals with complete scales.
ritem-rest is the correlation between an item and the scale that is formed by all other items.
α=Cronbach’s α of the scale excluding all but one of the items, except where ‘Total’ indicates Cronbach’s α for complete scale.
Table 4 Convergent construct validity—correlations between reference standards
Comparator Index
Baseline
N
Spearman’s correlation Pearson’s correlation
s=(95% CIs) r=(95% CIs)
MSK total (0, 56) OHS (0, 48) Hip 130 0.83 (0.77 to 0.88) 0.83 (0.77 to 0.88)
OKS (0, 48) Knee 125 0.88 (0.83 to 0.91) 0.89 (0.84 to 0.92)
OSS (0, 48) Shoulder 53 0.86 (0.78 to 0.92) 0.87 (0.79 to 0.93)
MSK total (0, 56) EQ-5D-5L Index (−0.59, 1) Total 525 0.81 (0.78 to 0.84) 0.80 (0.76 to 0.83)
Hip 141 0.76 (0.68 to 0.82) 0.77 (0.69 to 0.83)
Knee 123 0.78 (0.70 to 0.84) 0.75 (0.67 to 0.82)
Shoulder 58 0.84 (0.74 to 0.90) 0.81 (0.70 to 0.89)
Physio 203 0.82 (0.77 to 0.86) 0.81 (0.76 to 0.85)
MSK total (0, 56) MSK-PROM (0, 30) Total 203 0.81 (0.75 to 0.85) 0.82 (0.77 to 0.86)
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single MSK condition reference standards, particularly
with the Shoulder, Knee and Hip cohort reference stan-
dards (OSS=0.86, OKS=0.88 and OHS=0.83), show the
potential for the MSK-HQ to capture overall MSK health
status across different MSK conditions instead of relying
on existing condition-speciﬁc measures.
In order for healthcare services and individuals with
MSK conditions to better manage and monitor their
own health, appropriate clinical tools are required that
can capture the overall impact from ﬂuctuating symp-
toms.23 Previous research has sought to identify key
outcome domains for different musculoskeletal condi-
tions but have not sought to have one list of outcome
domains that can capture the overall impact for all MSK
conditions. For example, a work in 1998 by Deyo et al24
recommended the following core outcome domains for
low back pain disorders: pain (severity and frequency),
back-related function, generic well-being, difﬁculty with
social role/work and patient satisfaction with care. In
2014, four more domains were added to this list: pain
interference, depression, sleep disturbance and catastro-
phising.25 For patients with osteoarthritis, recommended
outcome domains include pain, functional impairment
and patient’s global assessment of change.26–28 Separately,
the International Classiﬁcation of Functioning, Disability
and Health has made individual recommendations for
different MSK conditions such as low back pain, chronic
widespread pain, ankylosing spondylitis, osteoporosis,
osteoarthritis and rheumatoid arthritis with the most
common domains across conditions being symptom sever-
ity (pain intensity), function (physical function, social
function, work function), generic well-being/quality of
life, patient’s global assessment of change, emotional
functioning, independence and patient satisfaction.29 It
can be seen that the domains included in the MSK-HQ
are largely consistent with all of the above recommenda-
tions, although the MSK-HQ does not measure domains
such as patient satisfaction or global assessment of
change which are typically captured at a single post-
treatment time point and not longitudinally over time.
A key vision of the MSK-HQ was to ﬁll the current gap
for a single broad health status measure instead of
relying on generic health tools such as the EQ-5D-5L
which have been shown to be less sensitive to change in
MSK populations.16 One key requirement for the
MSK-HQ yet to be tested is whether it is more sensitive
to change than the EQ-5D-5L. Follow-up data are cur-
rently being collected, to be reported separately in due
course. Such a tool would have strong potential in helping
to overcome current challenges in driving forward MSK
health service improvements caused by the use of so many
different PROMs across the pathway, despite a common
entry point for different MSK conditions. The use of the
MSK-HQ as a standard summative PROM across the MSK
pathway is initially supported by the results of this study,
although further research to examine the responsiveness
and applicability of this tool in other musculoskeletal
patient populations is recommended.30
In many long-term conditions, such as diabetes or
asthma, PROMs are also used to guide treatment. This
too was part of the vision for the MSK-HQ, to capture
an individual’s MSK health status at any given time and
thereby enable patients and their clinicians to monitor
progress over time and response to treatment. Individual
MSK-HQ items capturing ‘sleep’ or ‘physical activity’
could also enable speciﬁc patient needs to be tracked
over time and support the reporting of key issues to clin-
ical teams, thereby facilitating better shared decision-
making in consultations. Further strengths of the
MSK-HQ are its coproduction with patients, using
domains which have high face validity, are easy to under-
stand as well as being reliable and valid in heteroge-
neous MSK populations. However, a clear weakness of
this study is the lack of a rheumatology or pain clinic val-
idation cohort, although separate work is in progress to
test the MSK-HQ within a rheumatology setting and data
will be available soon. Another weakness is that missing
item rules and minimal clinically important differences
are not yet available for this measure, although future
studies will seek to address these issues. It is interesting
to note that MSK-HQ completion rates were below, or at,
3% when the tool was completed and checked in clinic
but were nearly 15% in the knee cohort where patients
completed the tool unsupervised at home. It will be
important for future studies to test whether electronic
data capture rather than the paper-based questionnaires
used in this study is able to reduce the number of
missing items in contexts where the tool is completed
unsupervised.
Important next steps for this research are to examine
the factor structure of the MSK-HQ as well as its respon-
siveness in comparison to condition-speciﬁc measures
such as the Oxford Hip and Knee Scores and generic
health status measures such as the EQ-5D-5L. Future
research opportunities for the MSK-HQ include its poten-
tial to help in reviewing patients MSK health status in
primary care chronic disease review clinics, and testing its
usefulness as a consultation prompt and care planning
tool to shape musculoskeletal consultation conversations
and ensure that individual issues are addressed.
CONCLUSION
A new PROM for a broad range of MSK conditions has
been successfully developed, called the MSK-HQ. This
novel PROM contains 14 items that capture key out-
comes that patients with a range of MSK conditions have
prioritised as important for use across the clinical
pathway. The MSK-HQ has also undergone initial psy-
chometric testing in four different MSK cohorts and
demonstrated high completion rates, excellent test–
retest reliability and strong convergent validity with refer-
ence standards, including the EQ-5D-5L, and Oxford
Hip, Knee and Shoulder scores. Ongoing follow-up
studies will examine the responsiveness and factor struc-
ture of the MSK-HQ in the future.
Hill JC, et al. BMJ Open 2016;6:e012331. doi:10.1136/bmjopen-2016-012331 9
Open Access
group.bmj.com on August 18, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
Author affiliations
1Arthritis Research UK Primary Care Centre, Keele University, Keele,
Staffordshire, UK
2Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal
Sciences, Botnar Research Centre, University of Oxford, Oxford, Oxfordshire,
UK
3Arthritis Research UK, London, UK
4Nuffield Department of Population Health, University of Oxford, Oxford,
Oxfordshire, UK
Acknowledgements The authors thank the clinical teams that participated in
the study and particularly the clinicians who agreed to take on the role of
research facilitators. The authors also thank patients for participating in the
study.
Contributors JCH, EH, BE, RF and AP contributed to the conception and
design of the work. JCH and AP were responsible for the development and
validation phases, respectively. SK and JCH were involved in the analyses and
JCH, SK, EB, RF and AP in the interpretation of the data. JCH, EB, HM, SB,
SS, KB and AP were involved in running the cohorts and collecting data. JCH,
SK, EB, HM, SB, SS, KMD, EH, JR, DB, SG-J, KB, BE, RF and AP were
involved in the drafting of the manuscript and its revision for important
intellectual content, and gave final approval for the manuscript.
Funding This project was funded by Arthritis Research UK (Ref. 20518). This
paper presents independent research (part) funded by the National Institute for
Health Research (NIHR). The views expressed are those of the authors and not
necessarily those of the NHS, the NIHR or the Department of Health. Jonathan
Hill is supported through a NIHR Research Professorship (NIHR-RP-011-015)
which is held by Nadine Foster. Elaine Hay is also a NIHR Senior Investigator.
The views expressed in this publication are those of the authors and not
necessarily those of the NHS, the NIHR or the Department of Health.
Competing interests None declared.
Patient consent All participants provided informed written consent and were
remunerated according to INVOLVE guidelines [11].
Ethics approval Ethics approval for the study’s development and validation
phases was obtained separately from the UK NHS Health Research Authority
National Research Ethics Service Committee (approval reference: 15/YH/0167
and 15/WA/0040).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Additional data can be accessed on request via the
Keele data repository at: http://www.keele.ac.uk/pchs/publications/
datasharingresources/
Open Access This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/
REFERENCES
1. Global Burden of Disease Study 2013 Collaborators. Global,
regional, and national incidence, prevalence, and years lived with
disability for 301 acute and chronic diseases and injuries in 188
countries, 1990–2013: a systematic analysis for the Global Burden
of Disease Study 2013. Lancet 2015;386:743–800.
2. NHS England. The NHS belongs to the people: a call to action.
London: NHS England 2013. https://www.england.nhs.uk/2013/07/
call-to-action/ (accessed 28th July 2016).
3. Department of Health. The musculoskeletal services framework: a
joint responsibility: doing it differently. London: DoH; 2006. http://
webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.
gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/
documents/digitalasset/dh_4138412.pdf (accessed 28th July 2016).
4. Kamaleri Y, Natvig B, Ihlebaek CM, et al. Localized or widespread
musculoskeletal pain: does it matter? Pain 2008;138:41–6.
5. Hartvigsen J, Natvig B, Ferreira M. Is it all about a pain in the back?
Best Pract Res Clin Rheumatol 2013;27:613–23.
6. Porcheret M, Jordan K, Jinks C, et al. Primary care treatment of
knee pain—a survey in older adults. Rheumatology (Oxford)
2007;46:1694–700.
7. Somerville S, Hay E, Lewis M, et al. Content and outcome of usual
primary care for back pain: a systematic review. Br J Gen Pract
2008;58:790–7.
8. Imison CNC, Goodwin N, Buck D, et al. Transforming our health
care system: ten priorities for commissioners. The Kings Fund,
2011.
9. U.S. Department of Health and Human Services FDA Center for
Drug Evaluation and Research, U.S. Department of Health and
Human Services FDA Center for Biologics Evaluation and Research,
U.S. Department of Health and Human Services FDA Center for
Devices and Radiological Health. Guidance for industry: patient-
reported outcome measures: use in medical product development to
support labeling claims: draft guidance. Health and Quality of Life
Outcomes. 2006;4:79. doi:10.1186/1477-7525-4-79
10. Health and Social Care Information Centre. Patient Reported
Outcome Measures. London: HSCIC; 2015. http://www.hscic.gov.uk/
proms (accessed 28th July 2016).
11. National Institute for Health Research. Budgeting for involvement:
Practical advice on budgeting for actively involving the public in
research studies. London: NIHR 2013. http://www.nihr.ac.uk/
documents/get-involved/INVOLVEMHRNBudgeting09Jul2013.pdf
(accessed 28th July 2016).
12. Delbecq AaV, AH. A group process model for problem identification
and program planning. J Appl Behav Sci 1971;VII:466–91.
13. Lewis C. Using the thinking-aloud method in cognitive interface
design. Technical Report IBM Research Report RC 9265, IBM,
Yorktown Heights, NY, 1982.
14. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary
testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life
Res 2011;20:1727–36.
15. Khan KA, Madan J, Petrou S, et al. Mapping between the Roland
Morris Questionnaire and generic preference-based measures.
Value Health 2014;17:686–95.
16. Hill JC, Thomas E, Hill S, et al. Development and validation of the
Keele Musculoskeletal Patient Reported Outcome Measure
(MSK-PROM). PLoS One 2015;10:e0124557.
17. Kamper SJ, Maher CG, Mackay G. Global rating of change scales:
a review of strengths and weaknesses and considerations for
design. J Man Manip Ther 2009;17:163–70.
18. Bond TaFC. Applying the Rasch model: Fundamental measurement
in the human sciences. 2nd edn. Mahwah N, ed. Lawrence Erlbaum,
2007.
19. de Vet HC, Terwee CB, Ostelo RW, et al. Minimal changes in health
status questionnaires: distinction between minimally detectable
change and minimally important change. Health Qual Life Outcomes
2006;4:54.
20. Legendre P. Species associations: the Kendall coefficient
of concordance revisited. J Agric Biol Environ Stat 2005;10:
226–45.
21. Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study
reached international consensus on taxonomy, terminology, and
definitions of measurement properties for health-related
patient-reported outcomes. J Clin Epidemiol 2010;63:737–45.
22. Donner A, Eliasziw M. Sample size requirements for reliability
studies. Stat Med 1987;6:441–8.
23. Greenhalgh J. The applications of PROs in clinical practice: what are
they, do they work, and why? Qual Life Res 2009;18:115–23.
24. Deyo RA, Battie M, Beurskens AJ, et al. Outcome measures for low
back pain research. A proposal for standardized use. Spine (Phila
Pa 1976) 1998;23:2003–13.
25. Deyo RA, Dworkin SF, Amtmann D, et al. Report of the NIH Task
Force on research standards for chronic low back pain. J Pain
2014;15:569–85.
26. Altman R, Brandt K, Hochberg M, et al. Design and conduct of
clinical trials in patients with osteoarthritis: recommendations from a
task force of the Osteoarthritis Research Society. Results from a
workshop. Osteoarthr Cartil 1996;4:217–43.
27. Bellamy N, Kirwan J, Boers M, et al. Recommendations for a core
set of outcome measures for future phase III clinical trials in knee,
hip, and hand osteoarthritis. Consensus development at OMERACT
III. J Rheumatol 1997;24:799–802.
28. Dougados M, Leclaire P, van der Heijde D, et al. Response criteria
for clinical trials on osteoarthritis of the knee and hip: a report of the
Osteoarthritis Research Society International Standing Committee
for Clinical Trials response criteria initiative. Osteoarthr Cartil
2000;8:395–403.
29. ICF. ICF Coresets for musculoskeletal conditions [01/04/2016].
https:// www.icf-research-branch.org/icf-core-sets-projects2/
musculoskeletal-conditions
30. Ellis B, FP, Hill JC, Price A. Bridging the musculoskeletal
measurement gap. J Trauma Orthop 2104;02.
10 Hill JC, et al. BMJ Open 2016;6:e012331. doi:10.1136/bmjopen-2016-012331
Open Access
group.bmj.com on August 18, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
across musculoskeletal care pathways
Health Questionnaire (MSK-HQ) for use
the Arthritis Research UK Musculoskeletal 
Development and initial cohort validation of
Fitzpatrick and Andrew Price
David Beard, Sion Glyn-Jones, Karen Barker, Benjamin Ellis, Ray
Blackburn, Stephanie Smith, Kate M Dunn, Elaine Hay, Jonathan Rees, 
Jonathan C Hill, Sujin Kang, Elena Benedetto, Helen Myers, Steven
doi: 10.1136/bmjopen-2016-012331
2016 6: BMJ Open 
 http://bmjopen.bmj.com/content/6/8/e012331
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/6/8/e012331
This article cites 19 articles, 2 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (166)Sports and exercise medicine
 (126)Rheumatology
 (218)Rehabilitation medicine
 (1072)Health services research
 (1634)Epidemiology
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on August 18, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
